Cargando…
A Phase 1 study for safety and pharmacokinetics of BIO101 (20‐hydroxyecdysone) in healthy young and older adults
BACKGROUND: Sarcopenia is an age‐related skeletal muscle disorder characterized by loss of muscle mass and strength leading to mobility disability. 20‐Hydroxyecdysone (20E) is a polyhydroxylated plant steroid that demonstrates pharmacological effects in many disease animal models including ageing/sa...
Autores principales: | Dioh, Waly, Tourette, Cendrine, Del Signore, Susanna, Daudigny, Louiza, Dupont, Philippe, Balducci, Christine, Dilda, Pierre J., Lafont, René, Veillet, Stanislas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235879/ https://www.ncbi.nlm.nih.gov/pubmed/37057316 http://dx.doi.org/10.1002/jcsm.13195 |
Ejemplares similares
-
20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases
por: Dinan, Laurence, et al.
Publicado: (2021) -
BIOPHYTIS BIO101 IN SARCOPENIA: UPDATE ON THE SARA PROGRAM: FROM SARA-INT TOWARDS THE PHASE 3 STUDY
por: Tourette, Cendrine, et al.
Publicado: (2022) -
A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality
por: Camelo, Serge, et al.
Publicado: (2021) -
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial
por: Dioh, W., et al.
Publicado: (2021) -
Developing new drugs that activate the protective arm of the renin–angiotensin system as a potential treatment for respiratory failure in COVID-19 patients
por: Latil, Mathilde, et al.
Publicado: (2021)